

1. General Information

Cohort ID	5020_21
Title (Study Name)	The CoVVacBoost Study
Principal investigator	Assoc. Prof. Martin Stradner, Prof. Ivo Steinmetz
Contact information	pm-biobank@medunigraz.at
Funding agency	----

2. Description

The aim of this study is to evaluate the ability of a COVID-19 booster vaccine to induce a salivary antibody response and to investigate a possible correlation with the serum antibody response and the cellular response. A quantitative and functional comparison of the salivary anti-SARS-CoV-2 antibody response before and after 3rd booster vaccination will be investigated. Volunteers, who get their 3rd vaccination at the "Impfstraße" at the LKH-Univ. Klinikum Graz are asked to participate in this study. Blood and saliva samples will be obtained during 3 visits.

Visit 1 (before the 3rd booster vaccination): Serology, PBMCs, saliva

Visit 2 (3 – 8 weeks after the 3rd booster vaccination): Serology, PBMCs, saliva

Visit 3: 6 months after the 3rd booster vaccination: Serology, saliva

The following data are collected for all participants: type of COVID-19 vaccinations, medical history (including immunosuppressive therapies, chronic graft versus host disease, severe opportunistic infections, prior vaccination history (types, titers if available), current and past disease including COVID-19), current medication, BMI, smoking habits.

3. Details

ICD 10/O codes / Healthy	healthy	
Key words	vaccination, COVID-19, SARS-CoV-2, mRNA vaccine, booster, 3 rd dose, Moderna, Comirnaty, AstraZeneca	
Collection / Cohort size 05/2022	1096 serum aliquots and 495 PBMC aliquots from 140 patients	
Informed Consent (IC)	<input checked="" type="checkbox"/> Broad Biobank IC	
	<input checked="" type="checkbox"/> Specific Study IC	
Status	<input checked="" type="checkbox"/> In progress / compl. date: 01/2023	
	<input type="checkbox"/> Completed	
Inclusion criteria	Age distribution	18+
	Sex distribution (f:m)	~50:50
	Others	<ul style="list-style-type: none"> • second dose AstraZeneca plus third dosis Moderna • second dose AstraZeneca plus third dosis Comirnaty • second dose Moderna plus third dosis Moderna • second dose Comirnaty plus third dosis Comirnaty
Earliest access	As of now	

	O-FIS Qualitätsmanagementsystem Formblatt Collection and Cohort Profile	CL312 Seite 2 von 2
---	---	------------------------

Quality-standards	<input checked="" type="checkbox"/> ISO 9001:2015 (SOPs)
Associated publications / references	-----

4. Material available (aliquot size) and storage conditions

Material	<input checked="" type="checkbox"/> Serum (580 µl)	<input checked="" type="checkbox"/> -80°C	<input type="checkbox"/> liq. N ₂
	<input checked="" type="checkbox"/> PBMC's	<input checked="" type="checkbox"/> -80°C	<input checked="" type="checkbox"/> liq. N ₂
	<input checked="" type="checkbox"/> Saliva	<input checked="" type="checkbox"/> -80°C	<input type="checkbox"/> liq. N ₂

Dokument erstellt (tt/mm/yyyy): 22/12/2021	Letzte inhaltliche Aktualisierung (tt/mm/yyyy): 20/05/2022
--	--